Physician profile
Marina Charitou
NPI 1518053248
$212,265.54
in general payments reported to CMS, 2019-2025
14 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,776 · 2021: $3,379 · 2022: $7,853 · 2023: $18K · 2024: $50K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $62K · Travel and Lodging: $17K · Food and Beverage: $7,136 · Consulting Fee: $6,503 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,643.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $61,873.00 |
| Travel and Lodging | $16,894.11 |
| Food and Beverage | $7,135.62 |
| Consulting Fee | $6,503.11 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $155,308.35 | 2019-2025 | Omnipod, Omnipod |
| Dexcom, INC. | $51,566.17 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $2,920.66 | 2024-2025 | Freestyle Libre Pro |
| Medtronic Minimed, INC. | $1,319.49 | 2019 | |
| Beta Bionics, INC. | $296.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $167.76 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $161.80 | 2019-2020 | |
| Cequr Corporation | $156.00 | 2024-2025 | Cequr Simplicity |
| Novo Nordisk INC | $153.10 | 2022-2025 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $128.31 | 2024 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $26.76 | 2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Antares Pharma, INC. | $21.22 | 2021 | |
| Mannkind Corporation | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Charitou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.